Countdown to the Conference:
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & Beyond
With continued advancements in screening platforms and proteomics, the covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology, immunology and CNS. We are witnessing this industry make great strides in utilizing novel covalent modalities and elucidating novel warheads to target amino acids beyond cysteine. However, developing covalent drugs remains no easy feat, as knowledge gaps persist in balancing reactivity and selectivity, de-risking the ligandability of alternative residues, and tackling PKPD disconnects and efficiency bottlenecks to successfully develop potent covalent drugs for unmet clinical need.
The 2nd Covalent Drug Discovery & Development Summit returns as the leading networking and learning opportunity for the covalent community, spanning every aspect of covalency from discovery to translation and clinical development, equipping 100+ proteomics, chemical biology, biochemistry and pharmacology leaders with the means to expand the druggable proteome.
FULL EVENT GUIDE
Room Block Now Available!
We are pleased to announce that for 2nd Covalent Drug Discovery & Development Summit, We have a dedicated room block at the conference hotel, Hilton Boston Logan Airport.
We have a discounted nightly room rate starting from $231 per night, from December 08 – December 12, 2024.
Book your reservations now to avoid disappointment!
Who’s Attending in December?
2024 Highlights
What’s New for 2024?
EXTENSIVE TECHNICAL CONTENT
Exploring the latest advancements in target selectivity, hit screening, lead optimization, and covalent warhead design to successfully identify, validate and clinically progress covalent drugs targeting transcription factors, E3 ligases, FGFRs, immunology targets and beyond!
A BRAND-NEW SPEAKING COHORT
from the likes of
EXPERT-LED WORKSHOPS
Interrogating & Optimizing Covalent Library Design to Improve the Generation of Viable Hits that Efficiently Engage the Target & Display Improved Safety Profiles
Fast-Track Target Validation to De-Risk Covalent Drug Discovery Pipelines in Oncology & Beyond